Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma

  • Technology appraisal guidance
  • TA1059
  • Published: 

History

Final draft guidance

Declaration of interests

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators